Utah Nurses Association
Zika Virus Update
The World Health Organization expects the Zika Virus to eventually spread to all of the Americas except for Canada and Chile, the two places where the Aedes species mosquito--a vector for the virus--does not live. Zika viral infection is asymptomatic in up to 80% of exposures or causes mild illness, such as fever, rash, muscle/joint pain and conjunctivitis. Severe disease and fatalities are rare. Health authorities, however, are becoming increasingly alarmed by the virus’ association with more severe clinical manifestations, including neurological and autoimmune-like illness, particularly Guillain-Barré syndrome (GBS) and congenital neurological malformations. Most disconcerting is a link between the Zika virus and microcephaly.
In 2016, Zika virus disease became a nationally notifiable condition. On January 26, 2016, the Center for Disease Control distributed the Interim Guidelines for the Evaluation and Testing of Infants with Possible Congenital Zika Virus Infection. In addition, the CDC has issued a Level 2 Travel Advisory for Mexico, Central and South America, the Caribbean, Samoa & Cape Verde.
Perinatal, in utero and possible sexual and transfusion transmission events have been reported. Zika viral RNA has been identified in asymptomatic blood donors. Other than universal precautions, no specific extraordinary countermeasures have been advised. No vaccine exists for the Zika virus. Mosquito protection and eradication remain the best defense for minimizing viral spread.
See also ANA Nurse Insider: http://www.nursingworld.org/HomepageCategory/NursingInsider/Zika-Virus-What-You-Need-to-Know.html
CDC Website: http://www.cdc.gov/zika/
CDC Interim Guidelines: http://www.cdc.gov/mmwr/volumes/65/wr/mm6503e3.htm
Protection against mosquitoes: http://www.cdc.gov/chikungunya/pdfs/fs_mosquito_bite_prevention_travelers.pdf
Mosquito Control Tips: http://www.cdc.gov/zika/pdfs/control_mosquitoes_chikv_denv_zika.pdf